The Glucagon-Like Peptide-1 Analogue Liraglutide Reduces Seizures Susceptibility, Cognition Dysfunction and Neuronal Apoptosis in a Mouse Model of Dravet Syndrome

• 主要な著者: Shenhai Liu (著者), Zhe Jin (著者), Yiling Zhang (著者), ShiKuo Rong (著者), Wenxin He (著者), Kuisheng Sun (著者), Din Wan (著者), Junming Huo (著者), Lifei Xiao (著者), Xinxiao Li (著者), Na Ding (著者), Feng Wang (著者), Tao Sun (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2020-02-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Dravet syndrome (DS) is a refractory epilepsy typically caused by heterozygous mutations of the Scn1a gene, which encodes the voltage-gated sodium channel Nav1.1. Glucagon-like peptide-1 (GLP-1) analogues, effective therapeutic agents for the treatment of diabetes, have recently become attractive tr...